New Danish biotech fund targeting 'approved' companies

A new Danish biotech fund prepares to invest in biotech companies with an FDA regulatory advantage. The ambition is to raise EUR 134m distributed between 20-40 companies, says experienced fund manager.
Peter Hildebrandt has more than 20 years' experience in biotech investments. | Photo: Privat
Peter Hildebrandt has more than 20 years' experience in biotech investments. | Photo: Privat
BY ALBERT RØNNING-ANDERSSON, MEDWATCH

These are thriving times for Danish biotech businesses, triumphant Genmab standing out as the perhaps most remarkable example and Thursday's million dollar bid on Nueveolution proving the potential of many more companies.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
  • Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
    Must contain at least 2 characters
    Must contain at least 2 characters

    Get full access for you and your coworkers

    Start a free company trial today

    Share article

    Sign up for our newsletter

    Stay ahead of development by receiving our newsletter on the latest sector knowledge.

    Newsletter terms

    Front page now

    Further reading